Latest Regulatory Approvals News

Red Mountain Mining reports promising gold assays at Oaky Creek and announces a fully funded trenching and soil sampling program to advance its Armidale Antimony-Gold project.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Johns Lyng Group has entered a binding scheme implementation deed with Pacific Equity Partners for a $1.1 billion acquisition at $4.00 per share, representing a significant premium and a 10.3x EV/EBITDA multiple. The transaction awaits shareholder and regulatory approvals, with major shareholder backing and a clear timetable set for late 2025.

Chariot Corporation Ltd is set to acquire a 66.7% interest in a substantial Nigerian lithium portfolio, marking a strategic entry into Africa’s burgeoning lithium sector with a US$10 million funding commitment.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

Race Oncology has secured key ethics approvals to launch its Phase 1 RC220 trial at two major Hong Kong hospitals, marking a strategic expansion beyond Australia to accelerate patient recruitment and explore cardioprotective benefits.

Orthocell has achieved a significant milestone by recording its first US sales revenue for Remplir™, its flagship nerve repair product, shortly after FDA clearance and initial surgical use.

Kinterra Capital GP Corp. II has increased its takeover offer for New World Resources Limited to A$0.062 per share, presenting shareholders with a superior all-cash proposal compared to rival Central Asia Metals Plc. The offer, backed by Kinterra’s 19.3% stake, aims for full ownership and potential delisting of NWR.

Emperor Energy has raised $3.7 million through a share placement to advance the Judith-2 appraisal well in Victoria’s Gippsland Basin, backed by independent resource validation and strategic infrastructure proximity.

Finbar Group has acquired the Palmyra development site from its JV partner, transforming it into a wholly-owned project valued at $88 million with settlement expected in early 2026.

Zenith Minerals has successfully raised A$3.5 million through a fully underwritten rights issue, positioning the company to fast-track exploration and resource growth at its key gold projects in Western Australia and Queensland.

Telix Pharmaceuticals has achieved a key milestone with its next-generation prostate cancer imaging agent, Gozellix, receiving a permanent HCPCS code from U.S. Medicare. This paves the way for broader reimbursement and market adoption starting October 2025.